{"entity":{"id":"nct07342725","kind":"trial","name":"Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Met","aka":[],"tldr":"A phase 1/2 trial of IBI363 in pancreatic cancer, run by Ruijin Hospital, not yet recruiting.","summary":"Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer is a phase 1/2, interventional study registered as NCT07342725 by Ruijin Hospital, with a registry enrolment figure of 48 participants, started 2026-01-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: IBI363 + chemotherapy. Conditions listed: Pancreatic Cancer Metastatic. Primary outcome: Adverse events (AEs); Progression-Free Survival(PFS). Pancreatic eligibility wording from the registry: \"* Histologically/cytologically confirmed, unresectable locally advanced or metastatic pancreatic cancer\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07342725","url":"https://clinicaltrials.gov/study/NCT07342725"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":["ibi363"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07342725","phase":"1/2","setting":"Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer","sponsor":"Ruijin Hospital","participation":[{"nct":"NCT07342725","source":"https://clinicaltrials.gov/study/NCT07342725","fetchedAt":"2026-10-07T16:55:41.039Z","studySha256":"f64d51f261e9eb4c6d8af1f08d81cc42637f15234dc56427fc35dca806e3dd0f","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-01-15","leadSponsor":"Ruijin Hospital","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":48,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2026-01-01","startedType":"estimated","enrolled":48,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07342725/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"drug":[{"id":"ibi363","kind":"drug","name":"IBI363","route":"/drugs/ibi363/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}